ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, ...

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate KLARITY, a Phase 2 clinical trial to investigate KIO-104 in patients ...

February is Age-Related Macular Degeneration Awareness (AMD) month. While AMD might be unfamiliar to some, nearly half a million people in Quebec are affected by this disease, which is the leading ...

The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib ...

Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.

Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

These are the best vitamins and supplements for eye health, which are great for supporting your vision and helping you take ...

Berlin: Bayer has submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research ...